Paige Mahaney - 28 Oct 2025 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Role
Chief Scientific Officer
Signature
/s/ Shagha Russell, Attorney-in-Fact
Issuer symbol
CCCC
Transactions as of
28 Oct 2025
Net transactions value
-$14,562
Form type
4
Filing time
30 Oct 2025, 16:30:04 UTC
Previous filing
18 Feb 2025
Next filing
18 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Mahaney Paige Chief Scientific Officer C4 THERAPEUTICS, INC., 490 ARSENAL WAY, SUITE 120, WATERTOWN /s/ Shagha Russell, Attorney-in-Fact 30 Oct 2025 0002040313

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CCCC Common Stock Options Exercise $0 +19,200 +22% $0.000000 105,000 28 Oct 2025 Direct F1
transaction CCCC Common Stock Tax liability $14,562 -5,644 -5.4% $2.58 99,356 28 Oct 2025 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the acquisition of shares of Common Stock upon vesting of a previously disclosed grant of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on October 28, 2024.
F2 Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.